These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24149085)

  • 1. HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption.
    de Goede AL; van Deutekom HW; Vrancken B; Schutten M; Allard SD; van Baalen CA; Osterhaus AD; Thielemans K; Aerts JL; Keşmir C; Lemey P; Gruters RA
    AIDS; 2013 Nov; 27(17):2679-89. PubMed ID: 24149085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
    Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
    AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef.
    Allard SD; Pletinckx K; Breckpot K; Heirman C; Bonehill A; Michiels A; van Baalen CA; Gruters RA; Osterhaus AD; Lacor P; Thielemans K; Aerts JL
    Vaccine; 2008 Jul; 26(29-30):3735-41. PubMed ID: 18539368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption.
    Allard SD; De Keersmaecker B; de Goede AL; Verschuren EJ; Koetsveld J; Reedijk ML; Wylock C; De Bel AV; Vandeloo J; Pistoor F; Heirman C; Beyer WE; Eilers PH; Corthals J; Padmos I; Thielemans K; Osterhaus AD; Lacor P; van der Ende ME; Aerts JL; van Baalen CA; Gruters RA
    Clin Immunol; 2012 Mar; 142(3):252-68. PubMed ID: 22177848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence evolution and escape from specific immune pressure of an HIV-1 Rev epitope with extensive sequence similarity to human nucleolar protein 6.
    Allard SD; de Goede AL; De Keersmaecker B; Heirman C; Lacor P; Osterhaus AD; Demanet C; Thielemans K; Gruters RA; Aerts JL
    Tissue Antigens; 2012 Mar; 79(3):174-85. PubMed ID: 22309258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Specific immune responses to human immunodeficiency virus type 1 Gag, Tat, Rev and Nef proteins].
    Zhai S; Kang WZ; Yu X; Wang SY; Walker BD; Altfeld M; Sun YT
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):175-9. PubMed ID: 15766402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
    Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
    Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Jacobson JM; Routy JP; Welles S; DeBenedette M; Tcherepanova I; Angel JB; Asmuth DM; Stein DK; Baril JG; McKellar M; Margolis DM; Trottier B; Wood K; Nicolette C
    J Acquir Immune Defic Syndr; 2016 May; 72(1):31-8. PubMed ID: 26751016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.
    Routy JP; Boulassel MR; Yassine-Diab B; Nicolette C; Healey D; Jain R; Landry C; Yegorov O; Tcherepanova I; Monesmith T; Finke L; Sékaly RP
    Clin Immunol; 2010 Feb; 134(2):140-7. PubMed ID: 19889582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
    Calarota SA; Kjerrström A; Islam KB; Wahren B
    Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
    Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef.
    Fischer M; Joos B; Hirschel B; Bleiber G; Weber R; Günthard HF;
    J Infect Dis; 2004 Dec; 190(11):1979-88. PubMed ID: 15529263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
    Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
    Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef.
    Navis M; Schellens IM; van Swieten P; Borghans JA; Miedema F; Kootstra NA; van Baarle D; Schuitemaker H
    J Infect Dis; 2008 Mar; 197(6):871-9. PubMed ID: 18279072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy.
    Thomas AS; Jones KL; Gandhi RT; McMahon DK; Cyktor JC; Chan D; Huang SH; Truong R; Bosque A; Macedo AB; Kovacs C; Benko E; Eron JJ; Bosch RJ; Lalama CM; Simmens S; Walker BD; Mellors JW; Jones RB
    PLoS Pathog; 2017 Sep; 13(9):e1006629. PubMed ID: 28931091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
    Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
    J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines.
    Ranki A; Lagerstedt A; Ovod V; Aavik E; Krohn KJ
    Arch Virol; 1994; 139(3-4):365-78. PubMed ID: 7832642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superimposed epitopes restricted by the same HLA molecule drive distinct HIV-specific CD8+ T cell repertoires.
    Sun X; Fujiwara M; Shi Y; Kuse N; Gatanaga H; Appay V; Gao GF; Oka S; Takiguchi M
    J Immunol; 2014 Jul; 193(1):77-84. PubMed ID: 24899498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-modulation of TCR/CD3 surface complexes after HIV-1 infection is associated with differential expression of the viral regulatory genes.
    Willard-Gallo KE; Furtado M; Burny A; Wolinsky SM
    Eur J Immunol; 2001 Apr; 31(4):969-79. PubMed ID: 11298321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals.
    Addo MM; Altfeld M; Rosenberg ES; Eldridge RL; Philips MN; Habeeb K; Khatri A; Brander C; Robbins GK; Mazzara GP; Goulder PJ; Walker BD;
    Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1781-6. PubMed ID: 11172028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.